tlooto
Sign up
Open AccessMedicine

Non‐bacterial cystitis with increased expression of programmed death‐ligand 1 in the urothelium: An unusual immune‐related adverse event during treatment with pembrolizumab for lung adenocarcinoma

Y. Ueki, M. Matsuki, T. Kubo, R. Morita, Y. Hirohashi, Syunsuke Sato, Ryota Horibe, K. Matsuo, T. Tsukahara, T. Kanaseki, Y. Takakuwa, M. Satoh, N. Itoh, T. Torigoe

2020.8.12IJU Case Reports

DOI: 10.1002/iju5.12211

tlooto Summary

Immune checkpoint inhibitors are now a standard therapeutic option for lung adenocarcinoma, however, they often induce various immune‐related adverse events.

Abstract

Immune checkpoint inhibitors are now a standard therapeutic option for lung adenocarcinoma. However, Immune checkpoint inhibitors often induce various immune‐related adverse events.

Citation format

UEKI, Y., et al. Non‐bacterial cystitis with increased expression of programmed death‐ligand 1 in the urothelium: An unusual immune‐related adverse event during treatment with pembrolizumab for lung adenocarcinoma. IJU Case Reports, 2020, 3: 266–269.